ERBB2 and cancer: The incidence of HER2 mutations can be as high as 6.7% in EGFR/ALK/ROS1-negative NSCLC24, especially in those who were negative for EGFR. Pan-cancer analysis shows that the most common HER2 mutations are S310F/Y (11.0%), A775_G776insYVMA (5.7%), L755P/S (4.6%), V842I (4.4%), and V777L/M (4.0%).